[The therapeutic effects of heparin on TNBS-induced rat colitis model].
OBJECTIVE
To study the relationship between coagulation abnormal and inflammatory in the TNBS induced rats colitis model as well as the therapeutic effect of heparin on this model.


METHODS
Forty SD-rats were separated into 4 groups randomly, including normal control group, colitis group, heparin group and SASP group. PT, APTT and the activity of antithrombin (AT) were chosen as indexs of coagulation. The level of damage and inflammatory state of the colitis rats were assessed by macroscopical score, histological score and the level of TNFalpha in each group.


RESULTS
Compared with normal control group, TNBS induced colitis group has a shorter PT [(14.83 +/- 0.45) s vs (16.68 +/- 1.08) s, P < 0.05] and APTT [(12.49 +/- 1.30) s vs (29.06 +/- 1.60) s, P < 0.05] and a lower activity level of AT [(111.33 +/- 8.50)% vs (122.13 +/- 3.52)%, P < 0.05]. In heparin group, PT, APTT were prolonged [PT: (17.83 +/- 0.78) s vs (14.83 +/- 0.45) s, P < 0.05, APTT: (53.34 +/- 9.49) s vs (12.49 +/- 1.30) s, P < 0.05] and AT activity was higher than colitis group [(131.67 +/- 6.92)% vs (111.33 +/- 8.50)%, P < 0.05]. SASP group has a similar data in PT, APTT compared with colitis group and no statistical significance (P > 0.05). The activity of AT in SASP group is higher than in colitis group [(122.33 +/- 5.82)% vs (111.33 +/- 8.50)%, P < 0.05]. The heparin therapy group showed lower macroscopical score (2.50 +/- 0.55 vs 4.75 +/- 1.16, P < 0.05), histological scores (3.83 +/- 0.41 vs 7.75 +/- 1.04, P < 0.05) and the level of TNFalpha [(84.75 +/- 18.03) ng/L vs (149.93 +/- 23.52) ng/L, P < 0.05] compared with the colitis group.


CONCLUSIONS
Coagulation was abnormality in the rat colitis model induced by TNBS; heparin therapy is effective in the colitis model. It seemed that the abnormality of coagulation plays an important role in the pathogenesis of the rat colitis model.
Peng
Tao
T
Department of Gastroenterology, Renmin Hospital, Peking University, Beijing 100044, China.
Liu
Yu-lan
YL
D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use*; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy*; D004195:Disease Models, Animal; D006493:Heparin / Q000627:therapeutic use*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D014302:Trinitrobenzenesulfonic Acid
D000925:Anticoagulants; D014302:Trinitrobenzenesulfonic Acid; D006493:Heparin